Serum antibody expression
Cargo | mRNA1 encoding a CD19/CD3 bispecific antibody
sales@dcchemicals.com
Lipid 01-1
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Serum antibody expression
Administration | Intravenous (tail vein)
Serum antibody expression
N/P ratio | Not reported for the cited experiment
Serum antibody expression
Exact formulation | 01-1 / DSPC / cholesterol / PEG lipid. Exact molar percentages and PEG-lipid identity are not resolved for this experiment.
Serum antibody expression
Model | NOD/SCID mice
Serum antibody expression
Dose | 1 μg mRNA per mouse, single dose
Serum antibody expression
Timepoints shown | 24 and 48 hours
Serum antibody expression
Comparators | 03-135, 03-208, 02-1 and 02-3
Antitumor activity in a humanized leukemia model
Cargo | mRNA1 encoding a CD19/CD3 bispecific antibody
Antitumor activity in a humanized leukemia model
Administration | Intravenous (tail vein)
Antitumor activity in a humanized leukemia model
N/P ratio | Not reported for the cited experiment
Antitumor activity in a humanized leukemia model
Exact formulation | 01-1 / DSPC / cholesterol / PEG lipid. Exact molar percentages and PEG-lipid identity are not resolved for this experiment.
Antitumor activity in a humanized leukemia model
Model | Human PBMC-engrafted M-NSG mice with Nalm6-luc leukemia
Antitumor activity in a humanized leukemia model
Dose | 3 μg mRNA per mouse, single dose
Antitumor activity in a humanized leukemia model
Comparators | PBS; non-specific mRNA (mRNA-NST), 3 μg/mouse once; recombinant antibody (blinatumomab), 3 μg/mouse daily for three administrations
Antitumor activity in a humanized leukemia model
Endpoint | Tumor bioluminescence (total flux), followed through day 14